Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Technology
Share your love
The Basics of Excimer Laser
In the field of ophthalmology, laser technology is used in many basic and clinical disciplines and specialities. It has played an important role in promoting the development of ophthalmology. Advancements in technology have allowed improvements in the surgical safety, efficacy, speed…
AsclepiX Therapeutics Raises $10M for Wet AMD Study
AsclepiX Therapeutics announced the completion of a $10 million Series A-3 financing aimed at advancing the clinical development of its leading candidate, AXT107 (gersizangitide), in patients diagnosed with wet AMD. “With the completion of this round, we are excited to…
Scientists Develop AI to Help Doctors Pick Best IOL Option
Scientists have developed computer models of patients’ eyes to determine the most suitable intraocular lenses and to offer patients a visual simulation of their expected vision with these lenses. Although millions of individuals have undergone LASIK eye surgery since it…
Astellas Signs Ophthalmic Gene Therapy Deal with 4DMT
Astellas Pharma has signed a license agreement that grants them the rights to utilize the intravitreal retinotropic R100* vector, developed by 4D Molecular Therapeutics (4DMT). This agreement enables Astellas to target one specific genetic target associated with rare monogenic ophthalmic…
Waterloo University’s Drug for AMD and DME
Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…
Novartis to Halt Development of GA Gene Therapy
After observing discouraging phase 2 clinical data, Novartis has opted to terminate the clinical advancement of its geographic atrophy gene therapy candidate GT005, a product it acquired through the acquisition of Gyroscope Therapeutics. The announcement was officially disseminated by investment…
Aegis and Northwell Launch AI Company Optain
Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…
Tenpoint Therapeutics Launches with $70M Financing
Tenpoint Therapeutics, a biotechnology company focused on vision-restoring engineered cell-based therapeutics and in vivo reprogramming for degenerative ocular diseases, has announced its launch with a $70 million Series A financing. The funding will be used to develop the company’s regenerative…
2023 Recap: Top 10 Contact Lenses and Technologies
In the ever-evolving landscape of ophthalmology, 2023 has proven to be a year of groundbreaking advancements in contact lens technology. From lenses that adapt to UV and temperature changes to intelligent lenses capable of diagnosing and treating glaucoma, the top…
Eye Atlas: A Key to Novel Eye Disease Therapies
Glaucoma and macular degeneration result in blindness for millions of people every year. These diseases have been linked to hundreds of genes that increase susceptibility, often serving as initial targets for therapies aimed at preventing or reversing blindness. However, the…